An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer

References

• Dastmalchi N, Safaralizadeh R, Baradaran B, et al. An update review of deregulated tumor-suppressive microRNAs and their contribution in various molecular subtypes of breast cancer. Gene 2020;729:144301.
   PubMed Web of Science ®Google Scholar
• He L, Lv Y, Song Y, et al. The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity. Cancer Manage Res. 2019;11:5765–5775.
   PubMed Web of Science ®Google Scholar
• Dastmalchi N, Khojasteh SMB, Nargesi MM, et al. The correlation between lncRNAs and Helicobacter pylori in gastric cancer. Pathogen Disease. 2019;77:9.
   Web of Science ®Google Scholar
• Mohammadzadeh A, Baradaran B, Dastmalchi N, et al. The correlation between helicobacter pylori infection and Lnc-OC1 expression in gastric cancer tissues in an Iranian population. Journal of gastrointestinal cancer. 2020;52(2):600–605.
   Web of Science ®Google Scholar
• Dastmalchi N, Safaralizadeh R, Nargesi MM. LncRNAs: potential Novel Prognostic and Diagnostic Biomarkers in Colorectal Cancer. Curr Med Chem. 2020;27(30):5067–5077.
   PubMed Web of Science ®Google Scholar
• Behzadi S, Baradaran B, Hosseinpourfeizi MA, et al. BC032913 as a Novel Antisense Non-coding RNA is Downregulated in Gastric Cancer. Journal of gastrointestinal cancer;2020. DOI: https://doi.org/10.1007/s12029-020-00517-6
   Google Scholar
• Zhang N, Zeng X, Sun C, et al. LncRNA LINC00963 Promotes Tumorigenesis and Radioresistance in Breast Cancer by Sponging miR-324-3p and Inducing ACK1 Expression. Molecular Therapy - Nucleic Acids. 2019;18:871–881.
   Google Scholar
• Liu L, Zhang Y, Lu J. The roles of long noncoding RNAs in breast cancer metastasis. Cell Death Dis. 2020;11(9):749.
   PubMed Web of Science ®Google Scholar
• Soudyab M, Iranpour M, The G-FS. Role of Long Non-Coding RNAs in Breast Cancer. Arch Iran Med. 2016;19(7):508–517.
   PubMed Web of Science ®Google Scholar
• Cao MX, Jiang YP, Tang YL, et al. The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity. Oncotarget. 2017;8(7):12472–12483.
   PubMedGoogle Scholar
• Wang L, Li J, Zhao H, et al. Identifying the crosstalk of dysfunctional pathways mediated by lncRNAs in breast cancer subtypes. Mol Biosyst. 2016;12(3):711–720.
   PubMedGoogle Scholar
• Redis RS, Sieuwerts AM, Look MP, et al. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget. 2013;4(10):1748–1762.
   PubMedGoogle Scholar
• Shirahama S, Miki A, Kaburaki T, et al. Long Non-coding RNAs Involved in Pathogenic Infection. Front Genet. 2020;11:454.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–1076.
   PubMed Web of Science ®Google Scholar
• Sunamura N, Ohira T, Kataoka M, et al. Regulation of functional KCNQ1OT1 lncRNA by beta-catenin. Sci Rep. 2016;6:20690.
   PubMed Web of Science ®Google Scholar
• Kong X, Liu W, Kong Y. Roles and expression profiles of long non-coding RNAs in triple-negative breast cancers. J Cell Mol Med. 2018;22(1):390–394.
   PubMed Web of Science ®Google Scholar
• Al-Thoubaity FK. Molecular classification of breast cancer: a retrospective cohort study. Annals of medicine and surgery. 2020;49: 44–48.
   PubMed Web of Science ®Google Scholar
• Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer. 2016;16(1):734.
   PubMed Web of Science ®Google Scholar
• Fragomeni SM, Sciallis A, Jeruss JS, et al. Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27(1):95–120.
   PubMed Web of Science ®Google Scholar
• Pecero ML, Salvador-Bofill J, Molina-Pinelo S. Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer. Cell Oncol. 2019;42(1):1–12.
   Web of Science ®Google Scholar
• Wang J, Chang S, Li G, et al. Application of liquid biopsy in precision medicine: opportunities and challenges. Front Med. 2017;11(4):522–527.
   PubMed Web of Science ®Google Scholar
• Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2:20360.
   Google Scholar
• Deva Magendhra Rao AK, Patel K, Korivi Jyothiraj S, et al. Identification of lncRNAs associated with early-stage breast cancer and their prognostic implications. Mol Oncol. 2019;13(6):1342–1355.
   PubMed Web of Science ®Google Scholar
• Pang B, Wang Q, Ning S, et al. Landscape of tumor suppressor long noncoding RNAs in breast cancer. J Exp Clin Cancer Res. 2019;38(1):79.
   PubMed Web of Science ®Google Scholar
• Amelio I, Bernassola F, Candi E. Emerging roles of long non-coding RNAs in breast cancer biology and management. Seminars in cancer biology. 2020;72:36–45.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang H, Xu M, et al. Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway. Hum Cell. 2018;31(3):232–241.
   PubMed Web of Science ®Google Scholar
• Xu X, Yuan X, Ni J, et al. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2. J Cell Physiol. 2021;236(2):1116–1130.
   PubMed Web of Science ®Google Scholar
• Mao Q, Lv M, Li L, et al. Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR-194-5p. J Cell Physiol. 2020;235(3):2668–2675.
   PubMed Web of Science ®Google Scholar
• Theodossiou TA, Ali M, Grigalavicius M, et al. Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy. NPJ Breast Cancer. 2019;5:13.
   PubMed Web of Science ®Google Scholar
• Shi YF, Lu H, Wang HB. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci. 2019;23(4):1563–1573.
   PubMed Web of Science ®Google Scholar
• Ai B, Kong X, Wang X, et al. LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1. Cell Death Dis. 2019;10(7):502.
   PubMed Web of Science ®Google Scholar
• Li X, Hou L, Yin L, et al. LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer. Journal of biosciences. 2020;45(1):45.
   PubMed Web of Science ®Google Scholar
• Li S, Zhou J, Wang Z, et al. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Biomed Pharmacother Biomed Pharmacother. 2018;104:451–457.
   PubMed Web of Science ®Google Scholar
• Luo L, Zhang J, Tang H, et al. LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. Cell Death Dis. 2020;11(5):329.
   PubMed Web of Science ®Google Scholar
• Rajagopal T, Talluri S, Venkatabalasubramanian S, et al. Multifaceted roles of long non-coding RNAs in triple-negative breast cancer: biology and clinical applications. Biochemical Society transactions;2020. DOI: https://doi.org/10.1042/BST20200666
   Google Scholar
• Fu J, Dong G, Shi H, et al. LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. J Cell Mol Med. 2019;23(7):4738–4745.
   PubMed Web of Science ®Google Scholar
• Sharma U, Barwal TS, Khandelwal A, et al. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3. Biochimie 2021;182:99–107.
   PubMed Web of Science ®Google Scholar
• Qin CX, Yang XQ, Jin GC, et al. LncRNA TSLNC8 inhibits proliferation of breast cancer cell through the miR-214-3p/FOXP2 axis. Eur Rev Med Pharmacol Sci. 2019;23(19):8440–8448.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhou Y, Zhao Y, et al. Long non-coding RNA TUSC8 inhibits breast cancer growth and metastasis via miR-190b-5p/MYLIP axis. Aging (Albany NY). 2020;12(3):2974–2991.
   PubMedGoogle Scholar
• Cedro-Tanda A, Rios-Romero M, Romero-Cordoba S, et al. A lncRNA landscape in breast cancer reveals a potential role for AC009283.1 in proliferation and apoptosis in HER2-enriched subtype. Sci Rep. 2020;10(1):13146.
   PubMed Web of Science ®Google Scholar
• Xu S, Kong D, Chen Q, et al. Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 2017;16(1):129.
   PubMed Web of Science ®Google Scholar
• Wu Z, Wang W, Wang Y, et al. Long noncoding RNA LINC00963 promotes breast cancer progression by functioning as a molecular sponge for microRNA-625 and thereby upregulating HMGA1. Cell Cycle. 2020;19(5):610–624.
   PubMed Web of Science ®Google Scholar
• Riffle S, Pandey RN, Albert M, et al. Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. BMC Cancer. 2017;17(1):338.
   PubMed Web of Science ®Google Scholar
• Garcia-Venzor A, Mandujano-Tinoco EA, Lizarraga F, et al. Microenvironment-regulated lncRNA-HAL is able to promote stemness in breast cancer cells. Biochim Biophys Acta Mol Cell Res. 2019;1866(12):118523.
   PubMed Web of Science ®Google Scholar
• Rani A, Stebbing J, Giamas G, et al. Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. Frontiers in endocrinology. 2019;10:245.
   PubMed Web of Science ®Google Scholar
• Ma T, Liang Y, Li Y, et al. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cell Signal. 2020;68:109536.
   PubMed Web of Science ®Google Scholar
• Qiu X, Dong J, Zhao Z, et al. LncRNA LINC00668 promotes the progression of breast cancer by inhibiting apoptosis and accelerating cell cycle. OncoTargets and Therapy. 2019;12:5615–5625.
   PubMed Web of Science ®Google Scholar
• Fan H, Yuan J, Li X, et al. LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression. Biomed Pharmacother Biomed Pharmacother. 2020;125:109987.
   PubMed Web of Science ®Google Scholar
• Wu G, Zhou H, Li D, et al. LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis. Exp Cell Res. 2020;396(2):112331.
   PubMed Web of Science ®Google Scholar
• Wang L, Luan T, Zhou S, et al. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p. Cancer Med. 2019;8(9):4389–4403.
   PubMed Web of Science ®Google Scholar
• Chen Q, Shen H, Zhu X, et al. A nuclear lncRNA Linc00839 as a Myc target to promote breast cancer chemoresistance via PI3K/AKT signaling pathway. Cancer Sci. 2020;111(9):3279–3291.
   PubMed Web of Science ®Google Scholar
• Dong H-T, Liu Q, Zhao T, et al. Long Non-coding RNA LOXL1-AS1 Drives Breast Cancer Invasion and Metastasis by Antagonizing miR-708-5p Expression and Activity. Molecular Therapy - Nucleic Acids. 2020;19:696–705.
   Google Scholar
• Hao A, Wang Y, Zhang X, et al. Long non-coding antisense RNA HYOU1-AS is essential to human breast cancer development through competitive binding hnRNPA1 to promote HYOU1 expression. Biochim Biophys Acta Mol Cell Res. 2021;1868(4):118951.
   PubMed Web of Science ®Google Scholar
• Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Therapeut Adv Med Oncol. 2019;11:1758835919833519.
   Web of Science ®Google Scholar
• Dong H, Hu J, Zou K, et al. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer. 2019;18(1):3.
   PubMed Web of Science ®Google Scholar
• Wang WT, Han C, Sun YM, et al. Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 2019;12(1):55.
   PubMed Web of Science ®Google Scholar
• Han M, Gu Y, Lu P, et al. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol Cancer. 2020;19(1):26.
   PubMed Web of Science ®Google Scholar
• Han J, Qu H, Han M, et al. MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer. Oncogene. 2021;40(4):833–847.
   PubMed Web of Science ®Google Scholar
• Won KA, Spruck C. Triple‑negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245–1261.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol. 2019;5(8):1132.
   PubMed Web of Science ®Google Scholar
• Bin X, Hongjian Y, Xiping Z, et al. Research progresses in roles of LncRNA and its relationships with breast cancer. Cancer cell international. 2018;18(1):179.
   PubMed Web of Science ®Google Scholar
• Ozes AR, Wang Y, Zong X, et al. Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep. 2017;7(1):894.
   PubMed Web of Science ®Google Scholar
• Qian Y, Shi L, Luo Z. Long Non-coding RNAs in Cancer: implications for Diagnosis, Prognosis, and Therapy. Frontiers in medicine. 2020;7: 612393.
   Web of Science ®Google Scholar
• Sole C, Arnaiz E, Manterola L, et al. The circulating transcriptome as a source of cancer liquid biopsy biomarkers. Seminars in cancer biology. 2019;58:100–108.
   PubMed Web of Science ®Google Scholar
• Pecero ML, Salvador-Bofill J, Molina-Pinelo S. Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer. Cell Oncol. 2019;42(1):1–12.
   Web of Science ®Google Scholar
• Rodriguez Bautista R, Ortega Gomez A, Hidalgo Miranda A, et al. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. Clin epigenetics. 2018;10(1):88.
   PubMed Web of Science ®Google Scholar
• Jin C, Yan B, Lu Q, et al. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development. Tumor Biology. 2016;37(6):7383–7394.
   PubMedGoogle Scholar
• Lin A, Li C, Xing Z, et al. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol. 2016;18(2):213–224.
   PubMed Web of Science ®Google Scholar
• Liu M, Xing L-Q, Liu Y-J. A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers. Medicine (Baltimore). 2017;96(9):e6222.
   PubMed Web of Science ®Google Scholar
• Kansara S, Pandey V, Lobie PE, et al. Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer. Cells 2020;9(6):6.
   Web of Science ®Google Scholar
• Luo Y, Yang J, Yu J, et al. Long Non-coding RNAs: emerging Roles in the Immunosuppressive Tumor Microenvironment. Front Oncol. 2020;10:48.
   PubMed Web of Science ®Google Scholar
• Pei X, Wang X, Li LH. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018;118(Pt A):24–30.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhao F, Yu X, et al. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med. 2020;18(1):442.
   PubMed Web of Science ®Google Scholar
• Bou-Dargham MJ, Liu Y, Qing-Xiang Amy S et al. Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3. PloS One. 2018;13(12):e0207799.
   PubMed Web of Science ®Google Scholar
• Liu Z, Mi M, Li X, et al. lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network. Front Genet. 2019;10:850.
   PubMed Web of Science ®Google Scholar
• Pal S, Garg M, Pandey AK. Deciphering the Mounting Complexity of the p53 Regulatory Network in Correlation to Long Non-Coding RNAs (lncRNAs) in Ovarian Cancer. Cells 2020;9(3):3.
   Web of Science ®Google Scholar
• Mei J, Hao L, Wang H, et al. Systematic characterization of non-coding RNAs in triple-negative breast cancer. Cell Prolif. 2020;53(5):e12801.
   PubMed Web of Science ®Google Scholar
• Huang D, Chen J, Yang L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19(10):1112–1125.
   PubMed Web of Science ®Google Scholar